Comparative Efficacy of Biologic Therapies for Psoriasis: Insights from Head-to-Head Studies

Biologic therapies have substantially transformed the management of moderate-to-severe psoriasis, but differences in efficacy, speed of response, durability, and safety reflect the distinct immunological pathways targeted by individual agents. The aim of this review is the analysis and comparison of particular biological agents in terms of efficacy and safety. Head-to-head trials consistently demonstrate that IL-17 and IL-23 inhibitors achieve greater skin clearance than first-generation TNF-α inhibitors. IL-17 blockade, particularly with agents targeting IL-17A, produces rapid clinical improvement by directly suppressing keratinocyte-driven inflammation. Dual IL-17A/IL-17F inhibition with bimekizumab may provide even greater clearance, although broader IL-17 inhibition is associated with a higher frequency of mucosal candidiasis. In contrast, selective IL-23 inhibition acts upstream by suppressing the differentiation and maintenance of pathogenic Th17 cells and appears to provide particularly durable disease control. Selective IL-23 inhibitors may also preserve potentially protective IL-12 signaling, distinguishing them from ustekinumab, which targets the shared p40 subunit. Safety profiles are generally favorable across biologic classes, although mechanism-specific risks include tuberculosis reactivation with TNF-α inhibitors, candidiasis with IL-17 inhibitors, and inflammatory bowel disease concerns with IL-17 blockade. Therefore, biologic selection should be individualized according to disease severity, required speed and durability of response, comorbidities, affected anatomical sites, safety considerations, dosing frequency, patient preferences and adherence goals. Current comparative evidence supports increasingly targeted approaches within the IL-23/IL-17 axis.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2026-11-18
DOI
https://doi.org/10.3390/ijms272210376
Primary Topic
Psoriasis: Treatment and Pathogenesis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Comparative Efficacy of Biologic Therapies for Psoriasis: Insights from Head-to-Head Studies

Adam Rafałowicz, Iwona Flisiak, Julia Nowowiejska
International Journal of Molecular Sciences
Psoriasis: Treatment and Pathogenesis
article

Comparative Efficacy of Biologic Therapies for Psoriasis: Insights from Head-to-Head Studies

Adam Rafałowicz, Iwona Flisiak, Julia Nowowiejska
article en

Abstract

Biologic therapies have substantially transformed the management of moderate-to-severe psoriasis, but differences in efficacy, speed of response, durability, and safety reflect the distinct immunological pathways targeted by individual agents. The aim of this review is the analysis and comparison of particular biological agents in terms of efficacy and safety. Head-to-head trials consistently demonstrate that IL-17 and IL-23 inhibitors achieve greater skin clearance than first-generation TNF-α inhibitors. IL-17 blockade, particularly with agents targeting IL-17A, produces rapid clinical improvement by directly suppressing keratinocyte-driven inflammation. Dual IL-17A/IL-17F inhibition with bimekizumab may provide even greater clearance, although broader IL-17 inhibition is associated with a higher frequency of mucosal candidiasis. In contrast, selective IL-23 inhibition acts upstream by suppressing the differentiation and maintenance of pathogenic Th17 cells and appears to provide particularly durable disease control. Selective IL-23 inhibitors may also preserve potentially protective IL-12 signaling, distinguishing them from ustekinumab, which targets the shared p40 subunit. Safety profiles are generally favorable across biologic classes, although mechanism-specific risks include tuberculosis reactivation with TNF-α inhibitors, candidiasis with IL-17 inhibitors, and inflammatory bowel disease concerns with IL-17 blockade. Therefore, biologic selection should be individualized according to disease severity, required speed and durability of response, comorbidities, affected anatomical sites, safety considerations, dosing frequency, patient preferences and adherence goals. Current comparative evidence supports increasingly targeted approaches within the IL-23/IL-17 axis.

International Journal of Molecular SciencesVol. 27(22)
Medical University of Białystok (PL)
Good health and well-being
Psoriasis: Treatment and Pathogenesis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon